Fremanezumab versus placebo for migraine prevention in patients with documented failure to up to four migraine preventive medication classes (FOCUS): a randomised, double-blind, placebo-controlled, phase 3b trial.
Lancet
; 394(10203): 1030-1040, 2019 09 21.
Article
in En
| MEDLINE
| ID: mdl-31427046
Full text:
1
Database:
MEDLINE
Main subject:
Migraine Disorders
/
Antibodies, Monoclonal
Type of study:
Clinical_trials
Limits:
Adolescent
/
Adult
/
Aged
/
Female
/
Humans
/
Male
/
Middle aged
Language:
En
Year:
2019
Type:
Article